Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
1.
Tumour Biol ; 35(2): 1649-52, 2014 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-24122202

RESUMO

Murine double minute 2 (MDM2) plays an important role in the carcinogenesis of many cancers including osteosarcoma. We performed a systemic review and meta-analysis to assess the effects of MDM2 polymorphisms on osteosarcoma risk and survival of patients with osteosarcoma. PubMed, Web of Science, and Wanfang databases were searched for eligible studies on the associations of MDM2 polymorphisms with osteosarcoma risk and survival of patients with osteosarcoma. Pooled odds ratio (OR) or hazard ratio (HR) with 95 % confidence intervals (95 % CIs) was used to assess the effects of MDM2 polymorphisms on osteosarcoma risk and survival of patients with osteosarcoma. Overall, MDM2 rs2279744 polymorphism was associated with a risk of osteosarcoma (allele model, OR = 1.60, 95 % CI 1.23-2.07, P < 0.001; codominant model, OR = 2.47, 95 % CI 1.46-4.19, P = 0.001; recessive model, OR = 2.13, 95 % CI 1.32-3.46, P = 0.002; dominant model, OR = 1.61, 95 % CI 1.12-2.33, P = 0.01). MDM2 rs1690916 polymorphism was also associated with a risk of osteosarcoma (OR = 0.60, 95 % CI 0.46-0.77, P < 0.001). However, MDM2 rs2279744 polymorphism was not associated with the overall survival of patients with osteosarcoma (codominant model, HR = 1.01, 95 % CI 0.53-1.91, P = 0.98; recessive model, HR = 1.07, 95 % CI 0.54-2.11, P = 0.85; dominant model, HR = 1.04, 95 % CI 0.65-1.66, P = 0.87). The meta-analysis suggests that MDM2 polymorphisms have some effects on the risk of osteosarcoma but have no effect on the survival of patients with osteosarcoma. Future studies are needed to further assess the effects of MDM2 polymorphisms on the risk and survival of osteosarcoma.


Assuntos
Neoplasias Ósseas/genética , Predisposição Genética para Doença , Osteossarcoma/genética , Proteínas Proto-Oncogênicas c-mdm2/genética , Animais , Neoplasias Ósseas/mortalidade , Neoplasias Ósseas/patologia , Estudos de Associação Genética , Humanos , Camundongos , Osteossarcoma/mortalidade , Osteossarcoma/patologia , Polimorfismo de Nucleotídeo Único , Fatores de Risco , Análise de Sobrevida
2.
Biomarkers ; 18(3): 216-20, 2013 May.
Artigo em Inglês | MEDLINE | ID: mdl-23557130

RESUMO

This study aims to detect S100A12 in serum and synovial fluid (SF) of knee osteoarthritis (OA) patients and to investigate their correlation with clinical severity of the disease. This study enrolled 198 OA patients and 84 healthy controls. The radiological/symptomatic severity of the disease was assessed by the Kellgren-Lawrence (KL) grading system/Western Ontario McMaster University Osteoarthritis (WOMAC) scores. We demonstrated that S100A12 levels in SF but not serum were independently associated with KL grades and WOMAC scores. These results suggested that the S100A12 in SF might be a potential biomarker for predicting the development and progression of knee OA.


Assuntos
Articulação do Joelho/metabolismo , Osteoartrite do Joelho/metabolismo , Proteínas S100/metabolismo , Índice de Gravidade de Doença , Líquido Sinovial/química , Idoso , Biomarcadores/metabolismo , Estudos de Casos e Controles , Progressão da Doença , Feminino , Humanos , Articulação do Joelho/patologia , Articulação do Joelho/cirurgia , Masculino , Pessoa de Meia-Idade , Osteoartrite do Joelho/diagnóstico , Osteoartrite do Joelho/patologia , Osteoartrite do Joelho/cirurgia , Proteína S100A12
SELEÇÃO DE REFERÊNCIAS
Detalhe da pesquisa